| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2308 | 2019 |
| Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients E de Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ... British journal of cancer 96 (10), 1504-1513, 2007 | 1321 | 2007 |
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ... The lancet oncology 12 (3), 236-244, 2011 | 821 | 2011 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 640 | 2013 |
| Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial MS Avila, SM Ayub-Ferreira, MR de Barros Wanderley, F das Dores Cruz, ... Journal of the American College of Cardiology 71 (20), 2281-2290, 2018 | 495 | 2018 |
| Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, D de Valeriola, ... British journal of cancer 92 (10), 1855-1861, 2005 | 410 | 2005 |
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised … SA Hurvitz, F Andre, Z Jiang, Z Shao, MS Mano, SP Neciosup, LM Tseng, ... The Lancet Oncology 16 (7), 816-829, 2015 | 337 | 2015 |
| Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor–positive patients JF Smyth, C Gourley, G Walker, MJ MacKean, A Stevenson, ... Clinical Cancer Research 13 (12), 3617-3622, 2007 | 237 | 2007 |
| HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials S Dent, B Oyan, A Honig, M Mano, S Howell Cancer treatment reviews 39 (6), 622-631, 2013 | 130 | 2013 |
| Novel cytotoxic drugs: old challenges, new solutions GFV Ismael, DD Rosa, MS Mano, A Awada Cancer treatment reviews 34 (1), 81-91, 2008 | 114 | 2008 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 112 | 2019 |
| The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours MS Mano, DD Rosa, E De Azambuja, GFV Ismael, V Durbecq Cancer treatment reviews 33 (1), 64-77, 2007 | 100 | 2007 |
| Current management of ovarian carcinosarcoma MS Mano, DD Rosa, E Azambuja, G Ismael, S Braga, V D'HONDT, ... International Journal of Gynecologic Cancer 17 (2), 2007 | 98 | 2007 |
| Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE EP Mamounas, M Untch, MS Mano, CS Huang, CE Geyer Jr, ... Annals of Oncology 32 (8), 1005-1014, 2021 | 97 | 2021 |
| Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy M Mano Cancer treatment reviews 32 (2), 106-118, 2006 | 84 | 2006 |
| Correlation between topoisomerase-IIα gene amplification and protein expression in HER-2 amplified breast cancer V Durbecq, C Desmed, M Paesmans, F Cardoso, A Di Leo, M Mano, ... International journal of oncology 25 (5), 1473-1479, 2004 | 82 | 2004 |
| Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma MS Mano, A Awada, A Di Leo, V Durbecq, M Paesmans, F Cardoso, ... Gynecologic oncology 92 (3), 887-895, 2004 | 78 | 2004 |
| Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an … C Bernard-Marty, M Mano, M Paesmans, C Accettura, R Munoz-Bermeo, ... Annals of oncology 14 (5), 693-698, 2003 | 66 | 2003 |
| Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy MS Mano, G Fraser, J Kerr, M Gray, V Evans, A Kazmi, P Canney The Breast 15 (1), 117-118, 2006 | 60 | 2006 |
| The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study … DD Rosa, J Bines, G Werutsky, CH Barrios, E Cronemberger, GS Queiroz, ... Breast Cancer Research and Treatment 183, 749-757, 2020 | 57 | 2020 |
